Related Experiment Video
Updated: Feb 15, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
Ren Matsuba1, Ikuro Matsuba2, Mototsugu Shimokawa3
1Department of Internal Medicine, Division of Metabolism and Endocrinology, St Marianna University School of Medicine, Kanagawa, Japan.
Abstract:
The impact of tofogliflozin, a sodium-glucose co-transporter-2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic-euglycaemic clamp method in a single-arm, open-label study. The following variables were compared between before and after tofogliflozin administration for 12 weeks in 16 patients with T2DM who were receiving dipeptidyl peptidase-4 inhibitor treatment: body weight (BW); blood pressure; glucose metabolism; liver function; lipid profile; and body composition. Peripheral glucose uptake (M value and M/I ratio) was examined by the hyperinsulinaemic-euglycaemic clamp method. After 12 weeks, there was a significant decrease (P < .001) in glycated haemoglobin, BW, body fat mass and lean body mass. Peripheral glucose uptake, which indicates insulin sensitivity, increased significantly (M value by 0.90 and M/I ratio by 0.49; both P < .05). The change in the M value after 12 weeks of tofogliflozin therapy was correlated with the change in body fat mass (P < .05). Tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake in patients with T2DM. These improvements were significantly correlated with reduction in body fat mass.
Insights
Tofogliflozin, a sodium-glucose co-transporter-2 inhibitor, significantly improved insulin sensitivity and glucose uptake in type 2 diabetes patients. These benefits were linked to a reduction in body fat mass after 12 weeks of treatment.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance and impaired glucose metabolism.
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors represent a therapeutic class that enhances glucose excretion, potentially impacting systemic glucose handling.
- Understanding the specific effects of SGLT2 inhibitors on peripheral glucose uptake is crucial for optimizing T2DM management.
Purpose of the Study:
- To evaluate the impact of tofogliflozin, an SGLT2 inhibitor, on peripheral glucose uptake in patients with T2DM.
- To assess changes in body composition, glucose metabolism, and other metabolic parameters following 12 weeks of tofogliflozin treatment.
- To investigate the correlation between improvements in glucose uptake and changes in body fat mass.
Main Methods:
- A single-arm, open-label study involving 16 patients with T2DM receiving dipeptidyl peptidase-4 inhibitor therapy.
- Peripheral glucose uptake was measured using the hyperinsulinaemic-euglycaemic clamp technique (assessing M value and M/I ratio).
- Key variables including body weight, blood pressure, glucose metabolism, liver function, lipid profile, and body composition were monitored before and after 12 weeks of tofogliflozin administration.
Main Results:
- Tofogliflozin treatment for 12 weeks resulted in significant reductions in glycated haemoglobin, body weight, body fat mass, and lean body mass (P < .001).
- Peripheral glucose uptake, a marker of insulin sensitivity, significantly increased (M value by 0.90, M/I ratio by 0.49; both P < .05).
- The improvement in the M value was significantly correlated with the reduction in body fat mass (P < .05).
Conclusions:
- Tofogliflozin effectively enhances insulin sensitivity and peripheral glucose uptake in patients with T2DM.
- The observed improvements in glucose metabolism are significantly associated with a decrease in body fat mass.
- These findings highlight a potential mechanism by which SGLT2 inhibition may benefit T2DM management beyond glycemic control.
Related Concept Videos
Decreased Body Temperature
Decreasing Function
Reduced Mass Coordinates: Isolated Two-body Problem
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Insulin Secretory Vesicles
Resistivity

